Howard Cohen, RPh, MS, FASHP, director of oncology pharmacy services, Smilow Cancer Center, Yale New Haven Health, discusses the rise of oral oncolytics in the treatment landscape during the 2018 NCODA Fall Summit.
Howard Cohen, RPh, MS, FASHP
Advertisement
Articles by Howard Cohen, RPh, MS, FASHP
Advertisement
Latest Updated Articles
The Rise of Oral OncolyticsOctober 31st 2018
Advertisement
Advertisement
Trending on OncLive
1
MONUMENTAL-3 Data Support Talquetamab Plus Daratumumab ± Pomalidomide as a New SOC in R/R Myeloma
2
Luspatercept Misses Primary RBC-TI End Point But Shows Clinically Meaningful Improvement for Anemia in Myelofibrosis
3
FDA Approves Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient mHSPC
4
Epcoritamab Significantly Improves PFS Vs Chemoimmunotherapy in R/R Large B-Cell Lymphoma
5